دورية أكاديمية

Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs

التفاصيل البيبلوغرافية
العنوان: Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs
المؤلفون: Ferretti S, Mercinelli C, Marandino L, Litterio G, Marchioni M, Schips L
المصدر: Research and Reports in Urology, Vol Volume 15, Pp 243-259 (2023)
بيانات النشر: Dove Medical Press, 2023.
سنة النشر: 2023
المجموعة: LCC:Diseases of the genitourinary system. Urology
مصطلحات موضوعية: metastatic castration resistant prostate cancer, chemotherapy, androgen-receptors axis targeted therapies, parp inhibitors, theragnostic, predictive biomarkers, Diseases of the genitourinary system. Urology, RC870-923
الوصف: Simone Ferretti,1,* Chiara Mercinelli,2,* Laura Marandino,2 Giulio Litterio,1 Michele Marchioni,1 Luigi Schips1 1Department of Medical, Oral and Biotechnological Sciences, G. d’Annunzio University of Chieti, Urology Unit, Chieti, Italy; 2Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy*These authors contributed equally to this workCorrespondence: Michele Marchioni, Department of Medical, Oral and Biotechnological Sciences, G. d’Annunzio University of Chieti, Urology Unit, Chieti, Italy, Tel +393296544866, Fax +390871357756, Email mic.marchioni@gmail.comAbstract: The therapeutic landscape of metastatic hormone sensitive and metastatic castration-resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment options for mCRPC, with insights on new available therapeutic strategies. Chemotherapy with docetaxel or cabazitaxel (for patients progressing on docetaxel), as well as treatment with androgen receptor axis targeted therapies, and Radium-223 are well-established treatment options for patients with mCRPC. The advent of theragnostic in prostate cancer established Lutetium-177 (177Lu)–PSMA-617 as a new standard of care for PSMA-positive mCRPC previously treated with ARAT and taxane-based chemotherapy. Olaparib, a poly-ADP-ribose polymerase (PARP) inhibitor, is approved for selected patients with mCRPC progressed on ARATs and in combination with abiraterone acetate as first-line treatment for mCRPC. Immunotherapy showed limited efficacy in unselected patients with mCRPC and novel immunotherapy strategies need to be explored. The search for biomarkers is a growing field of interest in mCRPC, and predictive biomarkers are needed to support the choice of treatment and the development of tailored strategies.Keywords: metastatic castration resistant prostate cancer, chemotherapy, androgen-receptors axis targeted therapies, PARP inhibitors, theragnostic, predictive biomarkers
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2253-2447
Relation: https://www.dovepress.com/metastatic-castration-resistant-prostate-cancer-insights-on-current-th-peer-reviewed-fulltext-article-RRU; https://doaj.org/toc/2253-2447
URL الوصول: https://doaj.org/article/fec6563f9cf047ea83aa64814cae7313
رقم الأكسشن: edsdoj.fec6563f9cf047ea83aa64814cae7313
قاعدة البيانات: Directory of Open Access Journals